Get the Stockscreener App
7.825
5.74%
0.415
Alumis Inc stock is traded at $7.825, with a volume of 810.95K.
It is up +5.74% in the last 24 hours and up +71.82% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$7.41
Open:
$7.41
24h Volume:
810.95K
Relative Volume:
1.05
Market Cap:
$761.14M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.2919
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
+2.55%
1M Performance:
+71.82%
6M Performance:
+127.10%
1Y Performance:
-8.47%
1-Day Range:
$7.41
$7.9699
1-Week Range:
$7.31
$7.9699
52-Week Range:
$2.7601
$10.49
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
7.83 | 773.56M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.29 | 109.90B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
728.98 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
476.75 | 61.42B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
924.70 | 56.36B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.80 | 44.06B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Can Alumis Inc. stock continue upward trendWeekly Trade Report & Weekly Breakout Watchlists - Newser
Why Alumis Inc. stock is a must watch in 2025Weekly Stock Recap & AI Driven Price Predictions - Newser
Alumis Insider Bought Shares Worth $1,310,677, According to a Recent SEC Filing - MarketScreener
Director Makes Major Investment in Alumis Inc. Stock! - TipRanks
Street Watch: Is Alumis Inc stock dividend yield sustainableMarket Rally & Stepwise Entry and Exit Trade Signals - BỘ NỘI VỤ
Major Stakeholders Show Confidence in Alumis Inc. with Significant Stock Purchases! - TipRanks
Tananbaum James B. buys Alumis Inc (ALMS) stock worth $532924 By Investing.com - Investing.com Canada
Tananbaum James B. buys Alumis Inc (ALMS) stock worth $532924 - Investing.com
[Form 4] ALUMIS INC. Insider Trading Activity - Stock Titan
Alumis Insider Bought Shares Worth $532,925, According to a Recent SEC Filing - MarketScreener
Owner Foresite Labs LLC Buys 72,212 ($532.9K) Of Alumis Inc [ALMS] - TradingView
Foresite Capital Management VI LLC's Strategic Acquisition of Al - GuruFocus
Director Makes a Bold Move with Major Stock Purchase in Alumis Inc. - TipRanks
Alumis director Akkaraju buys $905,349 in ALMS stock By Investing.com - Investing.com Canada
Alumis director Akkaraju buys $905,349 in ALMS stock - Investing.com
Alumis Inc.’s ESK-001 Study: A Potential Game-Changer for Hepatic Impairment Treatment? - MSN
How Alumis Inc. stock performs in rising dollar environmentEarnings Trend Report & Precise Swing Trade Entry Alerts - newser.com
Insider Trading Spotlight: Wednesday’s Top Buys and Sells Revealed By Investing.com - Investing.com Australia
Alumis Inc. Stock (ALMS) Opinions on Insider Purchases and Clinical Updates - Quiver Quantitative
Insider Trading Spotlight: Wednesday’s Top Buys and Sells Revealed - Investing.com
Analyzing drawdowns of Alumis Inc. with statistical tools2025 Price Momentum & Weekly High Return Stock Forecasts - newser.com
Alumis Insider Bought Shares Worth $1,529,865, According to a Recent SEC Filing - MarketScreener
Alumis Insider Bought Shares Worth $3,094,725, According to a Recent SEC Filing - MarketScreener
Alumis Inc: director Tananbaum buys $3.09 million in ALMS stock By Investing.com - Investing.com Nigeria
Foresite capital funds buy Alumis (ALMS) shares for $3.09 million By Investing.com - Investing.com Nigeria
Foresite Labs buys Alumis Inc (ALMS) shares worth $3.09 million By Investing.com - Investing.com Nigeria
Foresite capital funds buy Alumis (ALMS) shares for $3.09 million - Investing.com India
Foresite Labs buys Alumis Inc (ALMS) shares worth $3.09 million - Investing.com
Owner Foresite Capital Management VI LLC Buys 507,874 ($3.1M) Of Alumis Inc [ALMS] - TradingView
Alumis Inc (ALMS) director Akkaraju buys shares worth $1.53 million By Investing.com - Investing.com South Africa
Alumis Inc (ALMS) director Akkaraju buys shares worth $1.53 million - Investing.com
Dir Akkaraju Buys 241,338 ($1.5M) Of Alumis Inc [ALMS] - TradingView
Will Alumis Inc. outperform the marketDividend Hike & Real-Time Stock Entry Alerts - newser.com
Real time scanner hits for Alumis Inc. explainedQuarterly Earnings Summary & Long-Term Capital Growth Strategies - newser.com
Will Alumis Inc. continue its uptrendJuly 2025 Drop Watch & Expert Curated Trade Setup Alerts - newser.com
Hedge Fund and Insider Trading News: Tom Steyer, David Tepper, Davide Leone, Verition Fund Management, Balyasny Asset Management, Alumis Inc (ALMS), and More - Insider Monkey
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
| AKKARAJU SRINIVAS | Director |
Nov 28 '25 |
Buy |
7.64 |
38,702 |
295,683 |
730,499 |
| Foresite Capital Management VI | 10% Owner |
Nov 21 '25 |
Buy |
7.38 |
72,212 |
532,925 |
2,614,215 |
| Tananbaum James B. | Director |
Nov 21 '25 |
Buy |
7.38 |
72,212 |
532,925 |
2,614,215 |
| Foresite Labs, LLC | 10% Owner |
Nov 21 '25 |
Buy |
7.38 |
72,212 |
532,925 |
2,614,215 |
| AKKARAJU SRINIVAS | Director |
Nov 20 '25 |
Buy |
7.20 |
125,743 |
905,350 |
643,260 |
| Foresite Labs, LLC | 10% Owner |
Nov 19 '25 |
Buy |
6.56 |
190,500 |
1,249,680 |
2,542,003 |
| Foresite Labs, LLC | 10% Owner |
Nov 17 '25 |
Buy |
5.59 |
200,000 |
1,118,500 |
2,234,129 |
| Foresite Labs, LLC | 10% Owner |
Nov 18 '25 |
Buy |
6.19 |
117,374 |
726,545 |
2,351,503 |
| Foresite Capital Management VI | 10% Owner |
Nov 19 '25 |
Buy |
6.56 |
190,500 |
1,249,680 |
2,542,003 |
1.17%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):